Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera

被引:60
|
作者
Mullally, Ann [1 ]
Poveromo, Luke [1 ]
Schneider, Rebekka K. [1 ]
Al-Shahrour, Fatima [1 ,2 ]
Lane, Steven W. [3 ]
Ebert, Benjamin L. [1 ,2 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol,Dept Med, Boston, MA 02115 USA
[2] Broad Inst, Cambridge, England
[3] Queensland Inst Med Res, Brisbane, Qld 4006, Australia
基金
美国国家卫生研究院; 英国医学研究理事会;
关键词
V617F MUTATION OCCURS; TYROSINE KINASE JAK2; MYELOPROLIFERATIVE NEOPLASM; ESSENTIAL THROMBOCYTHEMIA; MOUSE MODEL; PROGENITOR; EXPRESSION; DISEASE; ERYTHROPOIETIN; TRANSFORMATION;
D O I
10.1182/blood-2012-01-402396
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the current model of the pathogenesis of polycythemia vera (PV), the JAK2V617F mutation arises in hematopoietic stem cells (HSCs) that maintain the disease, while erythroid precursor populations expand, resulting in excessive red blood cell production. We examined the role of these specific cell populations using a conditional Jak2V617F knockin murine model. We demonstrate that the most immature long-term (LT) HSCs are solely responsible for initiating and maintaining the disease in vivo and that Jak2V617F mutant LT-HSCs dominate hematopoiesis over time. When we induced Jak2V617F expression in erythropoietin receptor expressing precursor cells, the mice developed elevated hematocrit, expanded erythroid precursors, and suppressed erythropoietin levels. However, the disease phenotype was significantly attenuated compared with mice expressing Jak2V617F in LT-HSCs. In addition to developing a PV phenotype, all mice transplanted with Jak2V617F LT-HSCs underwent myelofibrotic transformation over time. These findings recapitulate the development of post-PV myelofibrosis in human myeloproliferative neoplasms. In aggregate, these results demonstrate the distinct roles of LT-HSCs and erythroid precursors in the pathogenesis of PV. (Blood. 2012; 120(1): 166-172)
引用
收藏
页码:166 / 172
页数:7
相关论文
共 50 条
  • [1] Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
    Mullally, Ann
    Bruedigam, Claudia
    Heckl, Dirk
    Poveromo, Luke
    Heidel, Florian H.
    Hill, Geoff
    Ebert, Benjamin L.
    Lane, Steven W.
    BLOOD, 2012, 120 (21)
  • [2] The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
    Jamieson, CHM
    Gotlib, J
    Durocher, JA
    Chao, MP
    Mariappan, MR
    Lay, M
    Jones, C
    Zehnder, JL
    Lilleberg, SL
    Weissman, IL
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (16) : 6224 - 6229
  • [3] Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
    Mullally, Ann
    Bruedigam, Claudia
    Poveromo, Luke
    Heidel, Florian H.
    Purdon, Amy
    Vu, Therese
    Austin, Rebecca
    Heckl, Dirk
    Breyfogle, Lawrence J.
    Kuhn, Catherine Paine
    Kalaitzidis, Demetrios
    Armstrong, Scott A.
    Williams, David A.
    Hill, Geoff R.
    Ebert, Benjamin L.
    Lane, Steven W.
    BLOOD, 2013, 121 (18) : 3692 - 3702
  • [4] TG101348, a potent, highly selective JAK2 inhibitor, inhibits colony formation in stem cells from polycythemia vera patients and prevents JAK2V617F-mediated splenomegaly and death in a mouse
    Hood, J.
    Doukas, J.
    Martin, M.
    Noronha, G.
    Jamieson, C.
    Soll, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm
    Castiglione, Melissa
    Mazzeo, Christopher
    Jiang, Ya-Ping
    Chen, Juei-Suei
    Yin, Wei
    Lin, Richard
    Zhan, Huichun
    BLOOD, 2019, 134
  • [6] JAK2V617F-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure
    Sano, Soichi
    Wang, Ying
    Yura, Yoshimitsu
    Sano, Miho
    Oshima, Kosei
    Yang, Yue
    Katanasaka, Yasufumi
    Min, Kyung-Duk
    Matsuura, Shinobu
    Ravid, Katya
    Mohi, Golam
    Walsh, Kenneth
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (06): : 684 - 697
  • [7] Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera
    Swierczek, Sabina I.
    Yoon, Donghoon
    Bellanne-Chantelot, Christine
    Kim, Soo Jin
    Saint-Martin, Cecile
    Delhommeau, Francois
    Najman, Albert
    Prchal, Josef T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (05): : 775 - 778
  • [8] JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
    Sureau, Lea
    Buors, Caroline
    Ianotto, Jean-Christophe
    Boyer, Francoise
    Tanguy-Schmidt, Aline
    Roy, Lydia
    Cayssials, Emilie
    Cailly, Laura
    Chomel, Jean-Claude
    Chauveau, Aurelie
    Orvain, Corentin
    Mansier, Olivier
    Ranta, Dana
    Robles, Margot
    Gyan, Emmanuel
    Herault, Olivier
    Nimubona, Stanislas
    Marchand, Tony
    Lippert, Eric
    Riou, Jeremie
    Ugo, Valerie
    Luque Paz, Damien
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [9] JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
    Léa Sureau
    Caroline Buors
    Jean-Christophe Ianotto
    Françoise Boyer
    Aline Tanguy-Schmidt
    Lydia Roy
    Emilie Cayssials
    Laura Cailly
    Jean-Claude Chomel
    Aurélie Chauveau
    Corentin Orvain
    Olivier Mansier
    Dana Ranta
    Margot Robles
    Emmanuel Gyan
    Olivier Hérault
    Stanislas Nimubona
    Tony Marchand
    Eric Lippert
    Jérémie Riou
    Valérie Ugo
    Damien Luque Paz
    Blood Cancer Journal, 12
  • [10] The study of Jak2 V617F mutation in polycythemia vera with zebrafish model
    Alvin CH Ma
    Alice MS Cheung
    Alister C Ward
    Wing-Yan Au
    Yok-Lam Kwong
    Raymond Liang
    Anskar YH Leung
    Cell Research, 2008, 18 : S141 - S141